Summary
The news that Cubist's Cubicin has been contaminated with 2-mercaptobenzothiazole (MBT) has caused great concern for patients. It appears that the MBT has leeched out of the Cardinal Health ReadyMED drug pumps that are used for delivering Cubicin. Regardless of who is at fault, everyone involved (Cubist, Cardinal, the FDA, doctors, and patients) have good reason to worry.
Analysis
Cubist is fairly sure that the ReadyMED pumps are responsible for the leeching of MBT into Cubicin solutions. Cardinal Health is currently investigating whether this is actually what happened. If the pumps are the source of MBT, then both Cardinal and Cubist are to blame.
Makers of drugs must perform extensive compatibility testing with approved delivery devices (syringes, pumps, tubing, etc.) to ensure that the drug formulation doesn't do exactly what Cubicin seems to be doing. If a change to the formulation isn't practical or desired, than a warning should be part of the drug product labeling (It's very likely that one will become part of it now).
Cubist may point the finger elsewhere, but at the end of the day, they are going to need to change their own practices and take responsibility for the usage of their products.
